Recent studies in zebrafish and mice demonstrated that proinflammatory signaling is a positive regulator of definitive hematopoietic development. Whether proinflammatory signaling regulates also human hematopoietic specification remains unknown. Here, we explored the impact of the proinflammatory cytokines tumor necrosis factor-α (TNFα), interferon-γ (IFNγ) and interleukin-1β (IL1β) on in vitro hematopoietic differentiation using human pluripotent stem cells (hPSCs). Gene expression analysis and ELISA revealed the absence of a proinflammatory signature during hematopoietic development of hPSCs. Functionally, the emergence of hemogenic endothelial progenitors (HEPs; CD31+CD34+CD45-or CD34+CD43-CD73-) and hematopoietic cells (CD43+CD45+) was not affected by treatment with increasing doses of TNFα, IFNγ and IL1β irrespective of the developmental window or the differentiation protocol used (embryoid body-or OP9 coculture-based). Similarly, knock-down of endogenous NF-kB signaling had no impact on hematopoietic differentiation of hPSCs. This study serves as a demonstration that TNFα, IFNγ and IL1β signals do not improve hematopoietic differentiation of hPSCs using current protocols and suggest that proinflammatory signaling is insufficient to drive definitive hematopoietic specification of human HSCs in vitro.
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INTRODUCTION
Hematopoiesis is a hierarchical process that is controlled by a rare population of multipotent hematopoietic stem cells (HSCs). In vivo, HSCs emerge directly from specialized hemogenic endothelial (HE) cells during development [1] [2] [3] , a process that is challenging to study in mammals because of the early developmental window in which they arise and the in utero location of the embryo [4] . Hematopoietic differentiation of human pluripotent stem cells (hPSCs), including embryonic stem cells (hESCs) and induced PSCs (hiPSCs), provides a unique opportunity to investigate HSC specification in vitro [5] [6] [7] ; however, bona fide HSCs have yet to be efficiently generated from hPSCs, in part due to an incomplete understanding of the multiple signaling pathways that govern HSC fate.
Inflammatory signaling is essential for stress hematopoiesis, either through increasing proliferation or by directing differentiation of HSCs towards myeloid and lymphoid lineages [8, 9] . Early studies suggested that proinflammatory cytokines, such IL1β and IL3, were important regulators of HSC development in the aorta-gonad-mesonephros (AGM) region [10] [11] [12] . More recently, a previously unrecognized link was established between inflammatory signaling and definitive hematopoietic emergence, in which tumor necrosis factor-α (TNFα)-and interferon-γ (IFNγ)-mediated proinflammatory signals positively regulated HSC emergence in zebrafish and mouse embryos [13] [14] [15] [16] [17] .
Although these findings advance our understanding of HSC specification, whether proinflammatory signaling is equally instructive in a human embryonic setting remains unknown [18] . Furthermore, it is unclear whether proinflammatory signals can be used to promote HSC emergence in vitro from hPSCs. Here we have explored the impact of CBI08#4 and CBI08#1 were maintained as described [19] . Approval from the Spanish National Embryo Ethical Committee was obtained to work with hPSCs. For embryoid body (EBs) generation, undifferentiated hPSCs were treated with collagenase IV, scraped off from the Matrigel, transferred to low-attachment plates and incubated overnight in mTESR1 medium (Stem Cell Technologies, Vancouver, Canada) supplemented with bone morphogenetic protein 4 (BMP-4; 50 ng/mL). The following day (day 1), the medium was changed for serum-free defined medium (StemPro-34; Invitrogen) supplemented with monothioglycerol (0.16 µM; Sigma), Holo-transferrin (150 µg/mL), 50 ng/mL BMP-4, and FGFb (10ng/mL). On the third day of differentiation, EBs were changed to differentiation medium (DM) comprising serumfree defined medium (StemPro-34; Invitrogen) supplemented with monothioglycerol, holo-transferrin, 50 ng/mL BMP-4, 300 ng/mL Fms-related tyrosine kinase 3 ligand (Flt-3L), 300 ng/mL stem cell factor (SCF), 10 ng/mL IL-3 and 10 ng/mL IL-6 [20, 21] .
TNFα, IFNγ and IL1β were added to cultures at indicated concentrations and refresh during medium changes. To promote definitive hematopoietic program EBs were treated with the GSK3 inhibitor CHIR99021 (3µM) from day 2 to day 3 of culture [22] .
All recombinant factors were purchased from R&D Systems. DM was replenished every 3 days. hPSC lines were also differentiated using OP9 co-culture system as described [23] .
hPSC lines were prepared as a suspension of small aggregates using collagenase IV followed by gentle scraping in DM (α-MEM basal medium, 10% non-heat-inactivated FBS, 100 µM monothioglycerol, and 50 mg/mL ascorbic acid) and plated on overgrown M A N U S C R I P T
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OP9 stroma in 4 mL of DM. On the following day, the medium was replaced with 4 mL of fresh DM to remove unattached cells. From day 3 of co-culture onwards, half-volume media changes were performed every other day. TNFα, INFγ, and IL1β were added to the culture at the indicated doses.
FACS analysis and sorting
Differentiating EBs and hPSC-OP9 co-cultures were dissociated and single cell suspension were stained with anti-CD235a-PE (BD), anti-CD73-BV510 (BD), anti- hematopoietic progenitor cells (CD34+CD45+) and non-hematopoietic cells (CD31-CD34-CD45-) were purified by FACSAria cell sorter as described [19] .
ELISA
Supernatants were collected during EB differentiation and the concentration of TNFα, IFNγ, and IL1β was quantified by ELISA following the manufacturer's instructions (Merck-Millipore).
Western blotting
Differentiating EBs were collected as indicated and treated with 20 ng/mL TNFα for 90 minutes. Western blotting was performed by standard methods. Primary antibodies used were anti-IκBα (Santa Cruz; sc-1643), anti-phospho-IκBα-Ser32/36 (92465) and anti-α-tubulin (both from Sigma).
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RNA Purification and Quantitative RT-PCR
Total RNA extraction and quantitative real-time PCR (qPCR) was performed as described [24] . Primer sequences are listed in Table S1 .
Statistical Analysis
All data are expressed as mean±SD. Statistical comparisons were performed with a paired Student's t-test (P < 0.05).
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RESULTS hPSC hematopoietic derivatives lack innate proinflammatory phenotype
Proinflammatory signaling positively regulates definitive HSC emergence in vertebrates [13, [15] [16] [17] , but whether it promotes in vitro HSC emergence from hPSCs remains unknown [4] . To address this, we analyzed the impact of TNFα, IFNγ and IL1β on hematopoietic development from two hESCs (H9 and AND1) and two hiPSC lines (CBI08#3 and CBI08#4). Hematopoietic differentiation of hPSCs progresses through two sequential stages: i) specification of hPSCs into hemogenic progenitors (HEPs) and ii) commitment of HEPs into CD45+ hematopoietic cells ( Figure 1A and 1B, and Figure S1A ) [19, 25, 26] . We first analyzed whether hematopoietic cells arising from Figure 2B ) [28] . To further determine whether TNFα signaling was relevant for hematopoietic emergence from hPSCs, endogenous TNFα-NF-kB activity was specifically inhibited by BAY65-5811 inhibitor [29] . FACS analysis confirmed that specific inhibition of endogenous NF-kB had no impact on HEPs specification or hematopoietic primitive commitment (Figure 2C ). IFNγ and ILβ signaling have also been shown to positively regulate blood emergence [10, 17] . We treated developing EBs with increasing concentrations of IFNγ (0, 10, 20 or 40 ng/ml) and ILβ (0, 5, 10 M A N U S C R I P T
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9 ng/ml) and consistently found no enhancement of hematopoietic emergence ( Figure   2D ).
Proinflammatory signaling does not promote hematopoietic emergence of hPSCs in OP9 co-culture
We next induced hematopoietic differentiation from hPSCs using an OP9-based coculture bi-dimensional system ( Figure 3A ) [19, 23] . Exposure of OP9-hPSC co-cultures to increasing concentrations of TNFα, IFNγ or ILβ failed to promote HEPs emergence and CD45+ hematopoietic cells differentiation ( Figure 3B) . Together with the demonstration of NF-kB activation by TNFα during EB development (Figure 2B ), our data obtained in OP9 co-culture system rule out the possibility that EB impermeability underlies the inability of these ligands to regulate HSC emergence. Collectively, these data demonstrate that TNFα, IFNγ or ILβ ligands do not promote hematopoietic specification of hPSCs irrespective of hPSC type or current differentiation regimen, suggesting that proinflammatory signaling is insufficient to improve HEPs emergence and blood generation from hPSCs.
TNFα and IFNγ γ γ γ do not enhance the emergence of definitive hematopoiesis
In vivo, both TNFα and INFγ have been shown to be dispensable for primitive hematopoiesis but critical for definitive HSC specification [13, [15] [16] [17] . To further assess the effect of proinflammatory signaling on the specification of definitive hematopoiesis, developing EBs were treated with the GSK-3 inhibitor CHIR99021 (d2-d3), a wellknown Wnt agonist [22, [30] [31] [32] coupled with continuous exposure to TNFα (20 ng/mL) or IFNγ (20 ng/mL) and hematopoietic cytokines ( Figure 4A ). We then FACS-analyzed day 9 EBs for several cell surface markers, including CD73 to distinguish hemogenic versus non-hemogenic progenitors [30] , CD235a, a marker of primitive hematopoietic progenitors [22] , and CD43 known to mark the onset of blood specification [31, 33] . At
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this stage of EB development, the majority of the CD31+CD34+ cells were negative for CD43 and CD235a, indicative of definitive hematopoietic program activation ( Figure   4B ) [22] . Consistent with our previous observations, treatment with TNFα and IFNγ failed to enhance HEP (CD34+CD45-CD73-or CD34+CD43-CD235a-) ( Figure 4B) and definitive hematopoietic cells (CD34 dim/+ CD43+CD45+CD235a-) development ( Figure 4C ). These findings suggest that proinflammatory signaling is insufficient for driving in vitro definitive hematopoietic development from hPSCs.
DISCUSSION
During the last decade, different protocols for hematopoietic differentiation of human (and mouse) PSCs have been developed and have made it possible to routinely produce blood cells [34] . However, the derivation of HSCs with long-term reconstitution potential from hPSCs remains a major goal for regenerative medicine and disease modeling [4, 35] . Proinflammatory signaling has been recently described as a positive regulator of definitive HSC emergence in vertebrates [13, [15] [16] [17] . These 
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